

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/02, 21/04, A61K 48/00, C12N 15/09		A1	(11) International Publication Number: WO 00/58332
			(43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/07634		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 23 March 2000 (23.03.00)		<p>Published <i>With international search report.</i></p>	
(30) Priority Data: 09/280,409 29 March 1999 (29.03.99) US			
(71) Applicants (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US). BAYLOR COLLEGE OF MEDICINE [US/US]; Texas Medical Center, One Baylor Place, Houston, TX 77030 (US).			
(72) Inventors; and (73) Inventors/Applicants (for US only): COWSERT, Lex, M. [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US). BENNETT, C., Frank [US/US]; 1347 Cassins Street, Carlsbad, CA 92008 (US). O'MALLEY, Burt, W. [US/US]; 639 Ramblewood, Houston, TX 77079 (US).			
(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).			
(54) Title: ANTISENSE MODULATION OF SRA EXPRESSION			
(57) Abstract			
<p>Antisense compounds, compositions and methods are provided for modulating the function or amount of SRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to SRA or nucleic acids encoding SRA. Methods of using these compounds for modulation of SRA levels and for treatment of diseases associated with SRA are provided.</p>			